You’ve probably heard about the rise of antibiotic-resistant bacteria worldwide – these ‘superbugs’ are incredibly dangerous, in part because they are immune to traditional small-molecule antibiotics. Modern researchers can design and manufacture next-generation antibiotics, made of large-molecule peptides, to treat the superbugs; potent as they are, though, these peptides are notoriously difficult to administer and require many injections to be effective. Our innovation, HIP-FNP, is a technology that protects peptides in the body, making administration significantly easier and reducing both the number of injections and amount of drug required for a cure. Unlike other peptide protection techniques, HIP-FNP is fully scalable, loses almost no drug during processing, and has low overhead. We have used HIP-FNP to protect eight major antibiotic peptides so far, and are currently implementing an industrial-scale proof-of-concept with a major pharma manufacturer. We believe the booming peptide market, estimated to reach $48 billion by 2025, is ripe for our technology, which reduces dosage amounts and improves antibiotic peptide administration: less drug, less often, less money – same cure.